Characteristics of patients (aged ≥ 12 yr) enrolled with physicians practising in a patient enrolment model by proportion of patients unvaccinated against SARS-CoV-2
| Characteristic | No. (%) of patients* | Standardized difference | ||
|---|---|---|---|---|
| Top 10% n = 962 826 | Remaining 90% n = 8 804 494 | Total n = 9 767 320 | ||
| Demographic | ||||
| Patient age, yr | ||||
| Mean ± SD | 46.9 ± 19.8 | 48.3 ± 20.2 | 48.1 ± 20.2 | 0.07 |
| Median (IQR) | 47 (31–62) | 49 (32–64) | 48 (32–64) | 0.07 |
| Patient age, yr | ||||
| 12–19 | 94 898 (9.9) | 805 632 (9.2) | 900 530 (9.2) | 0.02 |
| 20–34 | 202 005 (21.0) | 1 760 580 (20.0) | 1 962 585 (20.1) | 0.02 |
| 35–64 | 464 016 (48.2) | 4 132 346 (46.9) | 4 596 362 (47.1) | 0.03 |
| ≥ 65 | 201 907 (21.0) | 2 105 936 (23.9) | 2 307 843 (23.6) | 0.07 |
| Sex | ||||
| Male | 478 038 (49.6) | 4 129 671 (46.9) | 4 607 709 (47.2) | 0.05 |
| Female | 484 788 (50.4) | 4 674 823 (53.1) | 5 159 611 (52.8) | 0.05 |
| Immigrated within previous 10 yr | 69 428 (7.2) | 412 526 (4.7) | 481 954 (4.9) | 0.11 |
| Marginalization index | ||||
| Instability quintile | ||||
| Q1 (lowest) | 199 491 (20.9) | 2 027 338 (23.2) | 2 226 829 (22.9) | 0.06 |
| Q2 | 159 903 (16.7) | 1 760 796 (20.1) | 1 920 699 (19.8) | 0.09 |
| Q3 | 167 141 (17.5) | 1 650 968 (18.9) | 1 818 109 (18.7) | 0.04 |
| Q4 | 177 744 (18.6) | 1 531 088 (17.5) | 1 708 832 (17.6) | 0.03 |
| Q5 (highest) | 250 581 (26.2) | 1 778 839 (20.3) | 2 029 420 (20.9) | 0.14 |
| Material deprivation quintile | ||||
| Q1 (lowest) | 136 691 (14.3) | 2 204 260 (25.2) | 2 340 951 (24.1) | 0.28 |
| Q2 | 164 754 (17.3) | 1 962 959 (22.4) | 2 127 713 (21.9) | 0.13 |
| Q3 | 178 433 (18.7) | 1 701 938 (19.5) | 1 880 371 (19.4) | 0.02 |
| Q4 | 200 272 (21.0) | 1 522 899 (17.4) | 1 723 171 (17.8) | 0.09 |
| Q5 (highest) | 274 710 (28.8) | 1 356 973 (15.5) | 1 631 683 (16.8) | 0.32 |
| Dependency quintile | ||||
| Q1 (lowest) | 260 405 (27.3) | 2 357 931 (27.0) | 2 618 336 (27.0) | 0.01 |
| Q2 | 201 215 (21.1) | 1 747 940 (20.0) | 1 949 155 (20.1) | 0.03 |
| Q3 | 170 656 (17.9) | 1 527 286 (17.5) | 1 697 942 (17.5) | 0.01 |
| Q4 | 159 229 (16.7) | 1 489 584 (17.0) | 1 648 813 (17.0) | 0.01 |
| Q5 (highest) | 163 355 (17.1) | 1 626 288 (18.6) | 1 789 643 (18.4) | 0.04 |
| Ethnic diversity quintile | ||||
| Q1 (lowest) | 122 357 (12.8) | 1 457 758 (16.7) | 1 580 115 (16.3) | 0.11 |
| Q2 | 134 225 (14.1) | 1 532 873 (17.5) | 1 667 098 (17.2) | 0.10 |
| Q3 | 139 860 (14.6) | 1 618 432 (18.5) | 1 758 292 (18.1) | 0.10 |
| Q4 | 201 712 (21.1) | 1 832 769 (20.9) | 2 034 481 (21.0) | 0.00 |
| Q5 (highest) | 356 706 (37.4) | 2 307 197 (26.4) | 2 663 903 (27.5) | 0.24 |
| Income quintile | ||||
| Q1 (lowest) | 269 848 (28.1) | 1 442 262 (16.4) | 1 712 110 (17.6) | 0.28 |
| Q2 | 212 312 (22.1) | 1 663 125 (18.9) | 1 875 437 (19.2) | 0.08 |
| Q3 | 187 972 (19.6) | 1 810 032 (20.6) | 1 998 004 (20.5) | 0.03 |
| Q4 | 163 411 (17.0) | 1 898 678 (21.6) | 2 062 089 (21.2) | 0.12 |
| Q5 (highest) | 126 506 (13.2) | 1 969 581 (22.4) | 2 096 087 (21.5) | 0.24 |
| Comorbidity (ACG) | ||||
| No or low comorbidity (0–4) | 518 681 (53.9) | 4 700 743 (53.4) | 5 219 424 (53.4) | 0.01 |
| Moderate comorbidity (5–9) | 326 225 (33.9) | 3 111 382 (35.3) | 3 437 607 (35.2) | 0.03 |
| High comorbidity (≥ 10) | 117 920 (12.2) | 992 369 (11.3) | 1 110 289 (11.4) | 0.03 |
| Patient care and quality-of-care measures | ||||
| Continuity of care in previous 2 yr, %, median (IQR) | 96.9 (75.0–100) | 93.9 (75.0–100) | 94.1 (75.0–100) | 0.04 |
| Any virtual visits (telephone) in previous 6 mo | 441 955 (45.9) | 4 283 416 (48.7) | 4 725 371 (48.4) | 0.06 |
| Any in-person visits (office) in previous 8 mo | 504 009 (52.3) | 4 699 668 (53.4) | 5 203 677 (53.3) | 0.02 |
| Any colorectal cancer screening for patients aged 50–74 yr, n = 3 720 298 | 194 933 (54.2) | 2 140 145 (63.7) | 2 335 078 (62.8) | 0.19 |
| At least 1 Pap smear for females aged 21–69 yr in last 42 mo, n = 3 767 327 | 147 495 (41.0) | 1 683 560 (49.4) | 1 831 055 (48.6) | 0.17 |
| At least 1 LDL test for patients with diabetes in previous 2 yr, n = 1 160 604 | 98 371 (79.2) | 833 447 (80.4) | 931 818 (80.3) | 0.03 |
| At least 3 HbA1c tests for patients with diabetes in previous 2 yr, n = 1 160 604 | 78 223 (63.0) | 677 647 (65.4) | 755 870 (65.1) | 0.05 |
| SARS-CoV-2 vaccination | ||||
| Fully vaccinated (≥ 2 doses) patients as of Nov. 1, 2021 | 694 655 (72.1) | 7 570 735 (86.0) | 8 265 390 (84.6) | 0.35 |
Note: ACG = Adjusted Clinical Group, HbA1c = glycosylated hemoglobin, IQR = interquartile range, LDL = low-density lipoprotein, SD = standard deviation.
↵* Unless indicated otherwise. Some of the variable-specific totals will not add up to overall total because of inclusion and exclusion criteria or missing data.